1. emilyjaneclare
2. feruizdeluna
3. sandan331105
4. pcarter075
5. cbrclbwm9anr7ia
1.pcarter075 05/17/2018
Shares rallying nicely
2.cbrclbwm9anr7ia 10/07/2018
Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer from LIBRETTO-001 at the 88th Annual Meeting of the Ameri
3.pigseye83 03/26/2018
Loxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancer
4.sandan331105 06/03/2018
Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting
5.emilyjaneclare 03/26/2018
Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer
6.sandan331105 04/10/2018
Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics
7.emilyjaneclare 03/02/2018
Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial Results
8.feruizdeluna 05/17/2018
GREEEN
9.feruizdeluna 04/04/2018
Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
10.feruizdeluna 02/21/2018
Alert
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW